A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

Breast Cancer Research and Treatment

Volumn 110, Issue 2, 2008, Pages 327-335

  Johnston, Stephen R D ^a   Semiglazov, Vladimir F ^b   Manikhas, George M ^c   Spaeth, Dominique ^d   Romieu, Gilles ^e   Dodwell, David J ^f   Wardley, Andrew M ^g   Neven, Patrick ^h   Bessems, Annick ⁱ   Park, Youn C ⁱ   De Porre, Peter M ⁱ   Perez Ruixo, Juan J ⁱ   Howes, Angela J ⁱ  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^c City Oncology Dispensary   (Russian Federation)

^d CENTRE ALEXIS VAUTRIN   (France)

^e CENTRE VAL D AURELLE   (France)

^f Yorkshire Centre for Clinical Oncology   (United Kingdom)

^g CHRISTIE HOSPITAL   (United Kingdom)

^h Dienst Gyneacologische Oncologie   (Belgium)

ⁱ JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Breast cancer; Farnesyltransferase inhibitor; Letrozole; Tipifarnib

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIESTROGEN; ASPARTATE AMINOTRANSFERASE; ESTROGEN RECEPTOR; LETROZOLE; PLACEBO; PROTEIN FARNESYLTRANSFERASE INHIBITOR; TAMOXIFEN; TIPIFARNIB;

ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMNESIA; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHAGIA; DYSPNEA; FATIGUE; FEMALE; GASTRITIS; HUMAN; HYPERKALEMIA; HYPOKALEMIA; HYPONATREMIA; INCIDENCE; LEUKOPENIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOMA; SIDE EFFECT; STROKE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ESTROGEN RECEPTOR MODULATORS; FARNESYLTRANSTRANSFERASE; FEMALE; HUMANS; MIDDLE AGED; NITRILES; QUINOLONES; TIME FACTORS; TREATMENT OUTCOME; TRIAZOLES;

EID: 44849087679     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9726-1     Document Type: Article

References (32)

1. Clark GJ, Der CJ (1995) Aberrant function of the Ras signal transduction pathway in human breast cancer. Breast Cancer Res Treat 35:133-144
2. Clark GJ, Kinch MS, Gilmer TM et al (1996) Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. Oncogene 12:169-176
3. Norgaard P, Law B, Joseph H et al (1999) Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res 5:35-42
4. End DW, Smets G, Todd AV et al (2001) Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131-137
5. Kelland LR, Smith V, Valenti M et al (2001) Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin Cancer Res 7:3544-3550
6. Johnston SR, Hickish T, Ellis P et al (2003) Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer. J Clin Oncol 21:2492-2499
7. Nicholson RI, McClelland RA, Robertson JF, Gee JM (1999) Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 6:373-387
8. Simoncini T, Hafezi-Moghadam A, Brazil DP et al (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541
9. Levin ER (2003) Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol Endocrinol 17:309-317
10. Shou J, Massarweh S, Osborne CK et al (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96:926-935
11. Johnston SR (2005) Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations. Clin Cancer Res 11:889s-899s
12. Gee JM, Harper ME, Hutcheson IR et al (2003) The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 144:5105-5117
13. Martin LA, Head J, Pancholi S et al (2007) The farnesyl transferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in-vitro and in-vivo. Mol Cancer Ther (in press)
14. Ellis CA, Vos MD, Wickline M et al (2003) Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines. Breast Cancer Res Treat 78:59-67
15. Doisneau-Sixou SF, Cestac P, Faye JC et al (2003) Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression. Int J Cancer 106:789-798
16. Long BJ, Liu G, Marrinan CH et al (2004) Combining the farnesyl transferase inhibitor (FTI) Lonafarnib (SCH66336) with antiestrogens and aromatase inhibitors results in enhanced growth inhibition of hormone-dependent human breast cancer cells and tumor xenografts. Proc Am Assoc Cancer Res 45:A3868
17. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
18. Crul M, de Klerk GJ, Swart M et al (2002) Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol 20:2726-2735
19. Perez-Ruixo JJ, Piotrovskij V, Zhang S et al (2006) Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol 62:81-96
20. Dombernowsky P, Smith I, Falkson G et al (1998) Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461
21. Prendergast GC, Davide JP, deSolms SJ et al (1994) Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol Cell Biol 14:4193-4202
22. Miquel K, Pradines A, Sun J et al (1997) GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells. Cancer Res 57:1846-1850
23. Sepp-Lorenzino L, Rosen N (1998) A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells. J Biol Chem 273:20243-20251
24. Du W, Liu A, Prendergast GC (1999) Activation of the PI3′K-AKT pathway masks the proapoptotic effects of farnesyltransferase inhibitors. Cancer Res 59:4208-4212
25. Gutierrez MC, Detre S, Johnston S et al (2005) Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23:2469-2476
26. Lipton A, Leitzel K, Ali SM et al (2005) Serum HER-2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy. Cancer 104:257-263
27. Chan S, Scheulen ME, Johnston S et al (2005) Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23:5314-5322
28. Boulay A, Rudloff J, Ye J et al (2005) Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer. Clin Cancer Res 11:5319-5328
29. deGraffenried LA, Friedrichs WE, Russell DH et al (2004) Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin Cancer Res 10:8059-8067
30. Baslega J, Roche H, Fumoleau P et al (2005) Treatment of postmenopausal women with locally advanced or metastatic breast cancer with letrozole alone or in combinations with temsirolimus; a randomized 3-arm, phase 2 study. 28th annual San Antonio breast cancer symposium 94S:Abstract no. 1068
31. Kaufman B (2006) Trastuzumab plus anastrozole prolongs progression-free survival in postmenopausal women with HER2 positive, hormone-dependent metastatic breast cancer (MBC). European Society for Medical Oncology (ESMO) Congress 2006:Abstract no. LBA2
32. Moulder SL, Sparano JA, Kazi A et al (2005) The farnesyltransferase inhibitor (FTI) tipifarnib inhibits FPTase in vivo and enhances the efficacy of neoadjuvant dose-dense doxorubicin-cyclophosphamide (AC) in patients with locally advanced breast cancer 28th annual San Antonio breast cancer symposium 94S:Abstract no. 5061